Allergiezentrum-Hessen (AZH)

---

Studie: EudraCT Nr.: 2019-001792-37

• Sponsor: Novartis Extension
• Kurztitel: A multi-center, double-blinded and open-label extension study to evaluate the efficacy and safety of ligelizumab as retreatment, self-administered therapy and monotherapy in chronic spontaneous urticaria patients who completed studies CQGE031C2302, CQGE031C2303, CQGE031C2202 or CQGE031C1301
• Phase: III b
• Indikation: Chronische Urtikaria
• PI: Wolfgang Pfützner
• Studienstatus: Treatment Phase

---

Studie: EudraCT Nr.: 2017-001262-25

• Sponsor: Charite Berlin CHED
• Kurztitel: A randomized, double-blind, placebo-controlled, proof-of-concept, multicenter, 16-week treatment study with a 16 week follow-up period to assess the exploratory efficacy and safety of dupilumab  (anti-IL4Ra) in adult patients with cholinergic urticarial depite H1-antihistaminic treatment
• Phase: II a
• Indikation: Cholinerge Urtikaria
• PI: Wolfgang Pfützner
• Studienstatus: Treatment Phase

---

Studie: EudraCT Nr.: 2021-000424-35

• Sponsor: Novartis CLOU
• Kurztitel: A multicenter, randomized, double-blind, placebo-controlled Phase 3 study of remibrutinib (LOU064) to investigate the efficacy, safety and tolerability for52 weeks in adult chronic spontaneous urticarial patients inadequately controlled by H1-antihistamines
• Phase: III
• Indikation: Chronische Urtikaria
• PI: Wolfgang Pfützner (PI)
• Studienstatus: Screening ab Ende Feb.‘22 geplant

---

Studie: EudraCT Nr.: 2021-002967-23

• Sponsor: Almirall Advantage
• Kurztitel: Efficacy and safety of lebrikizumab in patients with AD not adequately controlled or non-eligible for cyclosporine
• Phase: II b
• Indikation: Atopische Ekzem
• PI: Wolfgang Pfützner
• Studienstatus: SIV steht noch aus

---

Studie: EudraCT Nr.: 2020-005900-21

• Sponsor: Janssen-ADM-LUNA
• Kurztitel: A phase 2a, multicenter, randomized, placebo-controlled, double-blind, interventional study to assess the efficacy, safety, pharmacokinetics and immunogenicity of multiple i.v. doses of bermekimab for treatment of adult participants with moderate-to-severe atopic dermatitis
• Phase: II a
• Indikation: Atopische Ekzem
• PI: Wolfgang Pfützner
• Studienstatus:​​ SIV im Februar’22 geplant

---